Warning: The NCBI web site requires JavaScript to function. more...
The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells.
Ghatge RP, Jacobsen BM, Schittone SA, Horwitz KB.
Breast Cancer Res. 2005;7(6):R1036-50. Epub 2005 Nov 2.
Related citations
Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.
Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD.
Mol Cell Endocrinol. 1999 Aug 20;154(1-2):11-20.
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors.
Cops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM, Tilley WD.
J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):236-43. Epub 2008 Apr 20.
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD.
Cancer Res. 2005 Sep 15;65(18):8487-96.
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, Figg WD, Hollingshead M, Hursting S, Berrigan D, Steinberg SM, Merino MJ, Steeg PS.
J Natl Cancer Inst. 2005 May 4;97(9):632-42.
Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids.
Hackenberg R, Schulz KD.
J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):113-7. Review.
Mechanisms involved in the evolution of progestin resistance in human breast cancer cells.
Murphy LC, Dotzlaw H, Wong MS, Miller T, Murphy LJ.
Cancer Res. 1991 Apr 15;51(8):2051-7.
Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor.
Hackenberg R, Hawighorst T, Filmer A, Nia AH, Schulz KD.
Breast Cancer Res Treat. 1993;25(3):217-24.
In vitro characterization of trimegestone: a new potent and selective progestin.
Zhang Z, Lundeen SG, Zhu Y, Carver JM, Winneker RC.
Steroids. 2000 Oct-Nov;65(10-11):637-43.
Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells.
Purmonen S, Manninen T, Pennanen P, Ylikomi T.
Oncol Rep. 2008 Jun;19(6):1627-34.
Suppression of parathyroid hormone-related protein messenger RNA expression by medroxyprogesterone acetate in breast cancer tissues.
Sugimoto T, Shiba E, Watanabe T, Takai S.
Breast Cancer Res Treat. 1999 Jul;56(1):11-23.
Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
Pennanen PT, Sarvilinna NS, Purmonen SR, Ylikomi TJ.
Steroids. 2009 Apr-May;74(4-5):404-9. Epub 2008 Dec 25.
Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells.
Sarvilinna N, Eronen H, Miettinen S, Vienonen A, Ylikomi T.
Int J Cancer. 2006 Feb 15;118(4):832-40.
The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA, Oza BP, Colomer R, Lupu R.
Int J Oncol. 2005 Jun;26(6):1507-15.
Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids.
Poulin R, Baker D, Poirier D, Labrie F.
Breast Cancer Res Treat. 1991 Jan-Feb;17(3):197-210.
Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Wu J, Brandt S, Hyder SM.
Mol Endocrinol. 2005 Feb;19(2):312-26. Epub 2004 Nov 4.
Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.
Salatino M, Beguelin W, Peters MG, Carnevale R, Proietti CJ, Galigniana MD, Vedoy CG, Schillaci R, Charreau EH, Sogayar MC, Elizalde PV.
Oncogene. 2006 Dec 14;25(59):7723-39. Epub 2006 Jun 26.
Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.
Breast Cancer Res Treat. 1989 Mar;13(2):161-72.
Role of the androgen receptor in human breast cancer.
Birrell SN, Hall RE, Tilley WD.
J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):95-103. Review.
Biphasic effect of medroxyprogesterone-acetate (MPA) treatment on proliferation and cyclin D1 gene transcription in T47D breast cancer cells.
Thuneke I, Schulte HM, Bamberger AM.
Breast Cancer Res Treat. 2000 Oct;63(3):243-8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on